Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ Capital MarketTotal Valuation
Telomir Pharmaceuticals, Inc. Common Stock carries a market capitalization of 76.56M, placing it among publicly traded companies globally.
| Market Cap | 76.56M |
| Enterprise Value | N/A |
Share Statistics
Telomir Pharmaceuticals, Inc. Common Stock currently has 68.77M shares outstanding.
| Shares Outstanding | 68.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 17.49 |
| P/TBV Ratio | 17.49 |
| P/FCF Ratio | -11.08 |
| P/OCF Ratio | -11.08 |
Financial Position
Telomir Pharmaceuticals, Inc. Common Stock maintains a current ratio of 16.14, meaning it holds 16.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.14 |
| Quick Ratio | 15.55 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -2,102.65 |
Financial Efficiency
| Return on Equity (ROE) | -1,885.50 |
| Return on Assets (ROA) | -189.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Telomir Pharmaceuticals, Inc. Common Stock's stock has declined approximately -37.3494% over the past 52 weeks. The 50-day moving average sits at 1.15, while the 200-day moving average is 1.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | -37.3494% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 1.24 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -6.09M, while operating income came in at -6.09M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -6.09M |
| Pretax Income | -5.88M |
| Net Income | -5.88M |
| EBITDA | -6.09M |
| EBIT | -6.09M |
| Earnings Per Share (EPS) | -0.14 |
Balance Sheet
Total book value stands at 5.03M, with working capital of 5.03M providing operational flexibility.
| Cash & Cash Equivalents | 5.17M |
| Total Debt | N/A |
| Net Debt | -5.17M |
| Equity (Book Value) | 5.03M |
| Book Value Per Share | 0.07 |
| Working Capital | 5.03M |
Cash Flow
Telomir Pharmaceuticals, Inc. Common Stock produced -4.91M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.91M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.91M |
| FCF Per Share | -0.12 |
Dividends & Yields
The company's payout ratio of 88.70 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 88.70 |
| Shareholder Yield | -10.60 |
| FCF Yield | -9.03 |
Scores
Telomir Pharmaceuticals, Inc. Common Stock posts an Altman Z-Score of 144.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 144.87 |